Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
about
Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucomaRNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclaseGenetic modification of hypertension by sGCα1Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVSRiociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Transforming growth factor-beta modulates the expression of nitric oxide signaling enzymes in the injured developing lung and in vascular smooth muscle cells.Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesIncorporation of tyrosine and glutamine residues into the soluble guanylate cyclase heme distal pocket alters NO and O2 binding.Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury.New perspectives for the treatment of pulmonary hypertensionAttenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.Structure and composition of pulmonary arteries, capillaries, and veins.cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxiaSoluble guanylate cyclase modulates alveolarization in the newborn lung.Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia.sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models.Gender-specific modulation of the response to arterial injury by soluble guanylate cyclase α1.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.Absence of the inflammasome adaptor ASC reduces hypoxia-induced pulmonary hypertension in mice.Pathophysiological mechanisms in acute mountain sickness.Effect of long-term high-altitude hypoxia on fetal pulmonary vascular contractility.Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide.Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats.The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension
P2860
Q26861763-613CA64B-CF21-46E5-818C-EAFC253B90E2Q27001569-44955CEB-E5E8-4D60-9F87-7DEFC8AD5AB5Q27001632-983797B6-CC0D-44CD-998A-32D379B5F9D2Q27021649-B5B6F6E4-6CCF-4E66-996E-81315EDF3201Q33596457-AF53FCB6-3261-4A94-88A4-B973876A2AD4Q33728207-7AEDA642-A7BD-443A-A4F7-51967F69A303Q33840756-07573D2A-DCAC-4324-8117-4AFB8F56B7FAQ33849207-5806361F-E8D2-4BC4-8414-AF448CD84B60Q33885131-1FC9720A-3B6B-4B06-A905-FE0DAC8FC13DQ34618219-37C05211-2DA4-421D-B92B-9FC44DF65442Q34903204-B2E38900-B8AF-4E1D-AFC6-7B1ED607EE4EQ36480012-EEC73ABE-5688-4E92-8703-93E025A846EFQ36532454-B6188889-F025-4B85-872D-3A6E20D49094Q36778449-B77831D3-81B4-477D-83B0-6181FD1D7DD8Q37002324-E8269C9F-F6EC-42AC-8498-4AEC70B66B5EQ37150753-2BEAF0D4-8FFF-45A9-A7C2-4A6B828A50DBQ37234894-109A8701-0206-418B-90F7-A719D8184CA5Q37297962-2632A1FA-A4F4-41B4-8851-58036BA31317Q37298332-A3F414DD-CC4D-4E97-ADAF-B2414C404B12Q37346565-4A9AD074-F95E-4CB8-82E0-DEFE91D22286Q37420916-5F69F2F8-044D-4014-96CB-5F6657E220A8Q37724192-94407893-00FD-491E-A8B4-AAC5EF5B918EQ41163325-09764F60-EF25-405A-973A-9044B9FA5345Q46211768-D7527F20-DDEE-4215-A07B-996C4D1E35C7Q46664719-F3C9339E-1975-452E-8D96-D91095403438Q46702844-1E0FD6B4-6242-4E47-83EE-EF190F45EC64Q46886439-F3EE56A8-EBC9-4C5A-84F9-727FCDF45EAEQ54714772-4DA68910-0CB0-4377-9A21-36A63E1919AAQ57167791-97004245-8908-4604-A099-BC970D5B7D1C
P2860
Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@en
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@nl
type
label
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@en
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@nl
prefLabel
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@en
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@nl
P2093
P1433
P1476
Soluble guanylate cyclase-alph ...... g response to chronic hypoxia.
@en
P2093
Amanda Graveline
Desire Collen
Emmanuel Buys
Fumito Ichinose
Hilde Gillijns
Kenneth D Bloch
Marc Swinnen
Marijke Pellens
Mieke Dewerchin
Patrick Sips
P304
P356
10.1161/CIRCULATIONAHA.106.677245
P407
P577
2007-08-06T00:00:00Z